(MedPage Today) -- Pediatric patients treated with acid-suppression drugs had more than double the rate of bacterial growth in the stomach compared with untreated children, a prospective cohort study showed.
Western Australia is increasingly on the radar of Chinese property investors, with commercial agents and developers hoping to replicate the success of their Sydney and Melbourne counterparts in sourcing significant capital from this cashed-up cohort.
In a note released Friday morning, Aegis Capital analyst Raghuram Selvaraju downgraded shares of Galectin Therapeutics (NASDAQ: GALT) from Buy to Hold.
The downgrade comes amid result concerns as to whether or not the company will be able to...
Ken Moelis didn’t set up his new firm in 2007 because he anticipated the crisis, he had just grown disgusted by what Wall Street had become. His new firm, an international and multidisciplinary provider of advice, thrived. This year, he took it...
Galectin Therapeutics Inc.
(Nasdaq: GALT), the leading developer of therapeutics that target galectin
proteins to treat fibrosis and cancer, today announced that the first patient
has been dosed in cohort 1 of the Company's Phase 1B clinical...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.